Skip to main content

Advertisement

SpringerLink
Log in

Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

This study was carried out to investigate mammary tumorigenesis in growth hormone (GH) deficient spontaneous dwarf rats (SDR). At 50–60 days of age, the rats were divided into five groups. Group 1 received bovine (b) GH (prolonged release formulation) administered at a dose of 40–50 mg/kg body wt. in 50 μl weekly injections; group 2 received recombinant human insulin-like growth factor-I (IGF-I) at a dose of 1 mg/kg body wt./day administered via osmotic pumps; animals in group 3 were fitted with subcutaneous silastic capsule containing 30 μg 17β-estradiol (E2) plus 30 mg progesterone (P4), replaced every 2 months; group 4 received both bGH and E2 plus P4 treatments at the same doses as above, and control animals (group 5) received sham treatments (vegetable oil injection, silastic capsules containing cellulose). After 1week of treatment, all animals were injected intraperitoneally with the carcinogen N-methyl-N-nitrosourea (MNU) at a dose of 50 mg/kg body wt. Other groups of animals, receiving identical hormonal treatment to those exposed to MNU, were treated for 10 days only and then sacrificed for assessment of circulating concentrations of hormones and mammary gland characteristics at the time of carcinogen exposure. The hormonal treatments of the animals exposed to the MNU were continued for an additional 20 weeks and mammary tumor development monitored by weekly palpation and tumors collected as necessary. The rats were weighed weekly. At the end of the treatment period, all animals were sacrificed and remaining tumors were collected. Rats in all groups continued to gain weight throughout the experimental period, but the largest weight gain was see in animals receiving GH either alone or with E2 and P4. Animals treated with IGF-I also gained weight compared to controls, but this weight gain was less than that seen in GH-treated rats. GH treatment alone increased mammary tumor incidence from 4.8% in controls to 100%. Average tumor load and latency in the GH-treated rats were 7.0 ± 0.8 tumors/tumor-bearing rat (mean±SEM) and 57.3 ± 2.7 days (mean±SEM), respectively. As in intact Sprague–Dawley rats, approximately 90% of the tumors that developed in the GH-treated rats were ovarian dependent for growth. IGF-I treatment also increased mammary tumor development to 62.5%. Average tumor load and latency in the IGF-I-treated rats were 1.6 ± 0.4 tumors/tumor-bearing rat (mean±SEM) and 96.2 ± 14.5 days (mean±SEM), respectively. However E2+P4 treatments did not significantly alter tumorigenesis and, surprisingly, simultaneous treatment with E2+P4 and GH obliterated the GH-stimulated increase in tumor development. Prolactin (PRL) did not appear to influence mammary tumorigenesis in the SDRs, as untreated SDRs had significantly elevated serum concentration of PRL as compared with normal Sprague–Dawley (SD) rats, whereas GH-treated SDRs had PRL levels similar to that of normal SD rats. No obvious structural characteristics were associated with high or low susceptibility to mammary tumorigenesis, as assessed by mammary gland whole mounts from the different animal groups sacrificed at the time of carcinogen administration.Enhanced expression of the extracellular signal-regulated kinase 1/2 (ERK1/2), and activation (phosphorylation) of ERK1/2 were associated with an increase in mammary tumorigenesis. Similarly, the expression of the estrogen receptor-α (ERα) was significantly elevated in animal groups with the highest susceptibility to tumorigenesis, whereas the levels of cyclin D1 expression were not related to mammary tumorigenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nandi S, Guzman RC, Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92: 3650–3657, 1995

    Google Scholar 

  2. Imagawa W, Pedchenko VK, Helber J, Zhang H: Hormone/ growth factor interactions mediating epithelial/stromal com-munication in mammary gland development and carcino-genesis. J Steroid Biochem Mol Biol 80: 213–230, 2002

    Google Scholar 

  3. Arafah BM, Manni A, Pearson OH: Effect of hypophysec-tomy and hormone replacement on hormone receptor levels and the growth of 7, 12, demethylbenz(a)anthracene-induced mammary tumors in the rat. Endocrinology 107: 1364–1369, 1980

    Google Scholar 

  4. Arafah BM, Finegan HM, Roe J, Manni A, Pearson OH: Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology 111: 584–588, 1982

    Google Scholar 

  5. Smith WC, Talamantes F: Identification and characteriza-tion of a heterogeneous population of growth hormone receptors in mouse hepatic membranes. J Biol Chem 262: 2213–2219, 1987

    Google Scholar 

  6. Laban C, Bustin SA, Jenkins PJ: The GH-IGF-I axis and breast cancer. Trends Endocrinol Metabolism 14: 28–34, 2003

    Google Scholar 

  7. Karey KP, Sirbasku DA: Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 b estradiol. Cancer Res 48: 4083–4092, 1988

    Google Scholar 

  8. Young S: Induction of mammary carcinoma in hypophy-sectomized rats treated with 3-methylcholanthrene, oestra-diol-17 b progesterone and growth hormone. Nature 190: 356–357, 1961

    Google Scholar 

  9. Rose DP, Gottardis M, Noonan JJ: Rat mammary carci-noma regressions during suppression of serum growth hormone and prolactin. Anticancer Res 3: 323–326, 1983

    Google Scholar 

  10. Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson O: High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 43: 237–242, 1992

    Google Scholar 

  11. Yang X-F, Beamer WG, Huynh H, Pollak M: Reduced growth of human breast cancer xenografts in hosts homo-zygous for the lit mutation. Cancer Res 56: 1509–1511, 1996

    Google Scholar 

  12. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK: Blockade of the type I somato-medin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84: 1418–1423, 1989

    Google Scholar 

  13. Girnita A, Girnita L, Prete Fd, Bartolazzi A, Larsson O, Axelson M: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236–242, 2004

    Google Scholar 

  14. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulin-like growth factor-1 (IGF-1)concentrations in human breast cancer. Eur J Cancer 29A: 492–497, 1993

    Google Scholar 

  15. Emerman JT, Leahy M, Gout PW, Bruchovsky N: Elevated growth hormone levels in sera from breast cancer patients. Hormone Metabolism Res 17: 421–424, 1985

    Google Scholar 

  16. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351: 1393–1396, 1998

    Google Scholar 

  17. Thordarson G, Jin E, Guzman RC, Swanson SM, Nandi S, Talamantes F: Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent changes in the hormonal environment or permanent biochemical altera-tions in the mammary epithelia? Carcinogenesis 16: 2847–2853, 1995

    Google Scholar 

  18. Swanson SM, Unterman TG: The growth hormone-de-cient spontaneous dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis 23: 977–982, 2002

    Google Scholar 

  19. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S: Prevention of mammary carcino-genesis by short-term estrogen and progestin treatments. Breast Cancer Res 6: R31–R37, 2004

    Google Scholar 

  20. Thompson HJ, Adlakha H: Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res 51: 3411–3415, 1991

    Google Scholar 

  21. Barnard R, Mulcahy J, Garcia-Aragon J, Wyse B, Owens PC, Rowlinson SW, Talamantes F, Baumbach WR, Waters MJ: Serum growth hormone binding protein and hepatic GH binding sites in the Lewis dwarf rat: effects of IGF-I and GH. Growth Regul 4: 147–154, 1994

    Google Scholar 

  22. Rasmussen SB, Young LJT, Smith GH: Preparing mam-mary gland whole mounts from mice. In: Ip MM, Asch BB (eds) Methods in Mammary Gland Biology and Breast Cancer Research Kluwer, New York, 2000, pp. 75–85

    Google Scholar 

  23. D' Ercole AJ, Stiles AD, Underwood LE: Tissue concen-trations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81: 935–939, 1984

  24. Freedman LS, Clifford C, Messina M: Analysis of dietary fat, calories, body weight, and the development of mam-mary tumors in rats and mice: a review. Cancer Res 50: 5710–5719, 1990

    Google Scholar 

  25. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT: The acid-labile subunit (ALS)of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 170: 63–70, 2001

    Google Scholar 

  26. Peter MA, Winterhalter KH, Boni-Schnetzler M, Froesch ER, Zapf J: Regulation of insulin-like growth factor-I (IGF-I)and IGF-binding proteins by growth hormone in rat white adipose tissue. Endocrinology 133: 2624–2631, 1993

    Google Scholar 

  27. Gosteli-Peter MA, Winterhalter KH, Schmid C, Froesch ER, Zapf J: Expression and regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein messen-ger ribonucleic acid levels in tissues of hypohpysectomized rats infused with IGF-I and growth hormone. Endocrinol-ogy 135: 2558–2567, 1994

    Google Scholar 

  28. Fielder PJ, Mortensen DL, Mallet P, Carlsson B, Baxter RC, Clark RG: Differential long-termeeffects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysecto-mized rats. Endocrinology 137: 1913–1920, 1996

    Google Scholar 

  29. Gargosky SE, Tapanainen P, Rosenfeld R: Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 comples in GH-de cient rats. Endocrinology 134: 2267–2276, 1994

    Google Scholar 

  30. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A: Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Develop Biol 229: 141–162, 2001

    Google Scholar 

  31. Ruan W, Kleinberg DL: Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocri-nology 140: 5075–5081, 1999

    Google Scholar 

  32. Abrams TJ, Guzman RC, Swanson SM, Thordarson G, Talamantes F, Nandi S: Changes in the parous rat mammary gland environment are involved in parity-asso-ciated protection against mammary carcinogenesis. Anti-cancer Res 18: 4115–4122, 1998

    Google Scholar 

  33. Huggins C, Moon RC, Morii S: Extinction of experimental mammary cancer, I.Estradiol-17 b and progesterone. Pro Natl Acad Sci USA 48: 379–386, 1962

    Google Scholar 

  34. Thordarson G, Lee AV, McCarty M, Van Horn K, Chu O, Chou Y-C, Yang J, Guzman RC, Nandi S, Talamantes F: Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats. Carcinogenesis 22: 2039–2047, 2001

    Google Scholar 

  35. Hamelers IHL, Steenbergh PH: Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocrine-Related Cancer 10: 331–345, 2003

    Google Scholar 

  36. LeRoith D, Roberts CT Jr.: The insulin-like growth factor system and cancer. Cancer Lett 195: 127–137, 2003

    Google Scholar 

  37. Zhu T, Goh ELK, Graichen R, Ling L, Lobie PE: Signal transduction via the growth hormone receptor. Cell Signal 13: 599–616, 2001

    Google Scholar 

  38. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491–1494, 1995

    Google Scholar 

  39. Cho H, Aronica SM, Katzenellenbogen BS: Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3 ¢, 5 ¢-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology 134: 658–664, 1994

    Google Scholar 

  40. El-Tanani MKK, Green CD: Interaction between estradiol and growth factors in the regulation of speci c gene expression in MCF-7 human breast cancer cells. J Steroid Biochem Molec Biol 60: 269–276, 1997

    Google Scholar 

  41. Ho KJ, Liao JK: Nonnuclear actions of estrogen. Arte-rioscler Thromb Vasc Biol 22: 1952–1961, 2002

    Google Scholar 

  42. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ: The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor a to the plasma membrane. Pro Natl Acad Sci USA 101: 2076–2081, 2004

    Google Scholar 

  43. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ: Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 69: 571–575, 1980

    Google Scholar 

  44. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KKY: Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metabolism 281: E1191–E1196, 2001

    Google Scholar 

  45. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CKW, Low TH, Leong GM, Ross RJM, Ho KKY: Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Pro Natl Acad Sci USA 100: 1016–1021, 2003

    Google Scholar 

  46. Bjornstrom L, Kilic E, Norman M, Parker MG, Sjoberg M: Cross-talk between Stat5b and estrogen receptor-a and-b in mammary epithelial cells. J Mol Endocrinol 27: 93–106, 2001

    Google Scholar 

  47. Bjornstrom L, Sjoberg M: Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16: 2202–2214, 2002

    Google Scholar 

  48. Faulds MH, Pettersson K, Gustafsson J-A, Haldosen L-A: Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 15: 1929–1940, 2001

    Google Scholar 

  49. Yamashita H, Iwase H, Yoyama T, Fujii Y: Naturally occurring dominant-negative Stat5 suppresses transcrip-tional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22: 1638–1652, 2003

    Google Scholar 

  50. Gullino PM, Pettigrew HM, Grantham FH: N-nitrosom-ethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst 54: 401–414, 1975

    Google Scholar 

  51. Arafah BM, Gullino PM, Manni A, Pearson OH: Effect of ovariectomy on hormone receptors and growth of N-nitrosomethylurea-induced mammary tumors in the rat. Cancer Res 40: 4628–4630, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular, Cell and Developmental Biology, Sinsheimer Laboratories, University of California, CA, USA

    Gudmundur Thordarson, Sheila Semaan, Caroline Low, Dafne Ochoa, Harriet Leong & Frank Talamantes

  2. Cancer Research Laboratory, University of California, CA, USA

    Lakshmanaswamy Rajkumar, Raphael C. Guzman & Satyabrata Nandi

Authors
  1. Gudmundur Thordarson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheila Semaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline Low
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dafne Ochoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Harriet Leong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lakshmanaswamy Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raphael C. Guzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satyabrata Nandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Frank Talamantes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thordarson, G., Semaan, S., Low, C. et al. Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments. Breast Cancer Res Treat 87, 277–290 (2004). https://doi.org/10.1007/s10549-004-9504-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-004-9504-2

Search

Navigation